A fully bioengineered, lab-grown human solid organ is successfully transplanted into a human patient before 20

Question

Six frontier AI models put this at 16% by 5 Oct 2031. Full reasoning from every model.

WillHappen.ai · Accepted Answer

16% — the median of 6 frontier models, resolving by 2031-10-05.

Answer

Gemini (Google): 14% — Thick solid organs still face fatal vascularization bottlenecks that five years of preclinical and clinical trials cannot bridge. Lab-grown bladders and skin succeeded, but fully vascularized kidneys, hearts, or livers have not survived long-term in large mammals. FDA IND approval requires multi-month non-human primate survival data, leaving insufficient time to clear Phase 1 human trials by 2031. Pivoting regulatory momentum toward xenotransplantation rather than de novo tissue synthesis draws capital away from bioengineering.

Answer

Claude (Anthropic): 12% — Turns on whether a fully bioengineered solid organ (not decellularized scaffold/xenotransplant) clears human trials by 2031. Current progress (bioprinted ear, mini-liver assist devices, bladder tissue engineering) hasn't reached vascularized solid organs like kidney/liver/heart. Vascularization and immune integration remain unsolved at scale; most 'bioengineered organ' headlines use decellularized scaffolds or animal-derived components, not… A breakthrough combining bioprinting with stem-cell derived vasculature achieving FDA/other regulatory human trial approval would be the key inflection point to watch.

Answer

GPT (OpenAI): 18% — The key hurdle is proving a vascularized, durable organ in first-in-human trials, not merely printing organ-like tissue. Hospitals, regulators, and sponsors must move from large-animal efficacy to an FDA/EMA-cleared human implant by October 2031. No fully lab-grown solid organ has yet shown long-term human function; prior clinical tissue engineering has mostly reached simpler grafts. A successful vascularized pig or primate organ with multi-year function by 2028 would materially raise the odds.

Answer

Grok (xAI): 18% — Vascularization and scaling of stem-cell tissue to a full-size, functional solid organ in five years. FDA/EMA first-in-human approval requires large-animal data showing months of organ function; none exists yet for a purely lab-grown kidney, liver or heart. Base rate is zero such transplants ever performed; organoids and printed patches remain millimetre-scale, so a 5-year window sits well below typical 10–15-year… A 2027 peer-reviewed large-animal full-organ graft with 6-month survival would most raise the odds.

Answer

DeepSeek (DeepSeek): 22% — Whether a lab-grown solid organ (not just tissue or a bladder) keeps a patient alive past transplant, with a documented survival. First-in-human solid organ attempts are already happening: a bioprinted trachea and 3D-printed ear have been implanted, but these are not vascularized solid organs. The gating step is a clinical trial showing sustained function; companies like United Therapeutics and IVIVA are targeting lung and kidney trials in the late 2020s… Base rate for a first-in-class organ transplant going from animal proof to documented human survival within five years is low, and regulatory review alone typically eats…

Answer

Qwen (Alibaba): 4% — No bioengineered solid organ has cleared even Phase I trials; the regulatory and vascularization hurdles make a 5-year window implausible. No lab-grown solid organ has entered a human transplant trial as of late 2025; the closest efforts (kidney, heart) remain at preclinical or early scaffold stages with… FDA approval for a novel bioengineered organ would require IND, Phase I safety data, and documented patient survival—historically a 7–12 year pipeline even for less… A development that would raise this: a major team (e.g., United Therapeutics, eGenesis, or a Chinese group) announcing a first-in-human transplant with survival data…

A fully bioengineered, lab-grown human solid organ is successfully transplanted into a human patient before 2031.

What each one said

A fully bioengineered, lab-grown human solid organ is successfully transplanted into a human patient before 2031.

The FDA suspends or revokes approval of an approved gene-editing therapy due to off-target side effects before 2028.

The US FDA approves an in vivo CRISPR-based gene editing therapy for common cardiovascular disease before 2030.

The FDA approves a therapeutic drug with an explicit indication to slow or reverse human biological aging before 2031.

A fully lab-grown solid human organ is successfully transplanted into a human patient before 2032.